Core Viewpoint - AI investors are facing challenges in 2026, with major AI stocks, including Nvidia, experiencing significant declines, yet Nvidia remains a company of interest due to its substantial market capitalization and potential undervaluation [1]. Group 1: Nvidia's Stock Performance - Nvidia's shares have decreased by 19% from their October high and are approaching a six-month low [1]. - Despite the drop, Nvidia's market capitalization stands at $4.07 trillion, raising questions about its valuation [1]. Group 2: Valuation Metrics - Nvidia's trailing P/E ratio is 35.7 and its trailing P/S ratio is 19.9, which are considered high compared to competitors like Alphabet, which has a P/E of 26.4 and a P/S of 8.6 [2]. - The trailing revenue and earnings metrics may not accurately reflect Nvidia's growth potential, as the company reported a 73% year-over-year revenue increase and a 98% year-over-year increase in per-share earnings in its most recent quarter [3]. Group 3: Forward-Looking Ratios - Nvidia's forward P/E ratio is 21.1, significantly lower than its trailing P/E, and its forward P/S ratio is 11.5, also lower than its trailing P/S [5]. - These forward-looking ratios could still appear high if Nvidia exceeds revenue expectations in the coming year [5]. Group 4: New Revenue Opportunities - Nvidia previously halted production of its H200 AI chip due to Chinese export controls, resulting in an estimated revenue loss of $8 billion per quarter [6]. - Recent reports suggest that Nvidia has resumed production of the H200 and may be developing a Chinese-friendly version of its Groq 3 AI inference chips, indicating potential new revenue streams [6].

Core Viewpoint - Nebius stock has emerged as a leader among 'neocloud' stocks in recent months, and a new data-center investment could further enhance its position [1] Group 1 - Nebius has been recognized for its strong performance in the 'neocloud' sector [1] - The potential investment in a new data center is expected to support Nebius's continued growth and leadership in the market [1]

Core Viewpoint - The CEO of Nextech3D.ai, Evan Gappelberg, has increased his ownership by purchasing 500,000 common shares at an average price of $0.12 CAD per share, indicating his belief that the stock is undervalued compared to the company's fundamentals [2][3][4]. Company Ownership and Investment - Following the recent acquisition, the CEO now owns over 30 million common shares, reflecting his confidence in the company's growth strategy and the adoption of its event technology platform [3][4]. - The purchase was made for investment purposes, emphasizing the CEO's commitment to the company's future [3]. Management Commentary - Gappelberg stated that the current market valuation does not reflect the operational milestones achieved in early 2026, describing the stock as "stupidly cheap" [4][5]. - He believes that a re-rating of the stock could occur as the market recognizes the company's 95% gross margins and 59% year-over-year revenue growth [5]. Operational Momentum - Nextech3D.ai has reported a strong start to 2026, achieving profitability in its Krafty Labs division and securing 50 new customer contracts since January [5]. - The company's unified AI platform is increasingly utilized by Fortune 1000 companies for various event management solutions, positioning it for sustained scalability within the $1.5 trillion global events industry [5][6].

Core Insights - OS Therapies, Inc. has submitted clinical and biomarker data from its Phase 2b trial of OST-HER2 to the FDA in preparation for a Pre-BLA Meeting expected in May 2026 [1][2] - The company reported a significant increase in net operating loss for 2025, amounting to $28.75 million compared to $8.82 million in 2024, primarily due to R&D and administrative expenses [5] Regulatory Developments - The FDA has acknowledged the strong safety profile of OST-HER2 and agreed on the use of immune biomarkers as surrogate clinical efficacy endpoints [2][3] - The company is preparing to submit Marketing Authorization Applications to the U.K. and European regulatory agencies in April 2026, with expected approval decisions in the second half of 2026 [2][3] Clinical Trial Progress - The Phase 2b trial of OST-HER2 demonstrated a 75% two-year overall survival rate and met the pre-specified threshold for event-free survival [3][9] - The company plans to initiate a confirmatory Phase 3 trial in Australia in the third quarter of 2026 [8][9] Financial Performance - The net loss per share for 2025 was $0.98 based on 290.235 million weighted average shares outstanding, compared to a loss of $1.28 per share in 2024 with 6.950 million shares [5] - The company raised $5.5 million in capital during the reporting period [9] Strategic Initiatives - OS Therapies acquired the listeria monocytogenes cancer immunotherapy platform from Ayala Pharmaceuticals, eliminating $20 million in development and commercial milestone payments [3][9] - The company has received multiple designations from the FDA and EMA, including Orphan Drug Designation and Fast Track Designation for OST-HER2 [10]

Group 1 - Jim Wyckoff has over 25 years of experience in stock, financial, and commodity markets, including roles as a financial journalist and reporter on commodity futures trading floors in Chicago and New York [1] - He has covered every futures market traded in the U.S. at various times throughout his career [1] - Jim is the owner of the "Jim Wyckoff on the Markets" analytical, educational, and trading advisory service [2] Group 2 - He has worked as a technical analyst for Dow Jones Newswires and as a senior market analyst with TraderPlanet.com [2] - Jim is a consultant for the "Pro Farmer" agricultural advisory service and was the head equities analyst at CapitalistEdge.com [2] - He holds a degree in journalism and economics from Iowa State University [2] Group 3 - Daily updates and technical analysis are provided by Jim on Kitco.com, including both AM and PM roundups [3]

Core Insights - Novo Nordisk has launched a subscription program for its Wegovy obesity drug, aimed at providing cash-paying patients with lower and more predictable monthly prices [1][2] Subscription Program Details - Eligible patients can select from three, six, or twelve-month subscription plans for the Wegovy injection or the two highest doses of the newly launched pill, with longer plans offering reduced monthly costs [2] - The company anticipates that patients could save up to $1,200 annually on the injection and up to $600 on the pill compared to paying for individual doses each month [2] - Patients will benefit from flat monthly prices even if they switch to different doses during the subscription period [3] Market Positioning and Patient Support - This subscription model is described as a unique opportunity to assist patients in both initiating and maintaining their therapy, addressing pricing fluctuations [4] - The program is expected to be available through several telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame, and Hims & Hers, with plans for additional partners in the future [3] Challenges in Treatment Adherence - A significant challenge in the use of GLP-1 medications, such as Wegovy, is the difficulty patients face in maintaining treatment, with a study indicating that approximately 65% of patients with obesity discontinue treatment within a year due to various factors [5]

Core Insights - NUBURU, Inc. has announced an initial deployment order for its portable directed-energy laser dazzler system aimed at counter-drone defense applications from a tier-one government organization [1] Company Overview - NUBURU, Inc. operates as a dual-use Defense & Security platform company, focusing on non-kinetic effects, directed-energy technologies, electronic warfare, and software-orchestrated defense systems [1]

Core Viewpoint - PVH Corp. is set to release its fourth-quarter earnings on March 31, with expectations of a slight increase in earnings per share and revenue compared to the previous year [1]. Financial Performance - Analysts predict PVH will report quarterly earnings of $3.30 per share, an increase from $3.27 per share in the same period last year [1]. - The consensus estimate for PVH's quarterly revenue is $2.43 billion, up from $2.37 billion reported last year [1]. Dividend Information - On February 4, PVH declared a quarterly cash dividend of 3.75 cents per share [1]. Stock Performance - PVH shares experienced a slight increase of 0.2%, closing at $66.56 on Monday [1].

Core Viewpoint - PVH Corp. is expected to report an increase in quarterly earnings and revenue for its fourth quarter, indicating positive financial performance [1] Financial Performance - Analysts anticipate PVH will report quarterly earnings of $3.30 per share, an increase from $3.27 per share in the same period last year [1] - The consensus estimate for PVH's quarterly revenue is $2.43 billion, up from $2.37 billion reported last year [1] Dividend Information - On February 4, PVH declared a quarterly cash dividend of 3.75 cents per share [1] Stock Performance - PVH shares increased by 0.2%, closing at $66.56 on Monday [1]

Core Viewpoint - The outgoing head of Airbus Helicopters emphasizes the necessity for deeper European collaboration in defense procurement to avoid escalating costs associated with fragmented national projects [1][3]. Group 1: European Defense Collaboration - CEO Bruno Even advocates for European cooperation in defense, arguing that nationalistic approaches could lead to unsustainable costs [3][5]. - Even asserts that the future replacement for military helicopters must remain a European initiative, countering claims that European cooperation is ineffective [2][4]. Group 2: NH90 Program Status - Even defends the NH90 program, stating that past issues related to availability and delays have been resolved, and the program is now on track [9][10]. - The NH90 program has received renewed support, with NATO approving a version for French special forces, and total orders have reached 639 helicopters, with over 500 currently in service [9][10]. Group 3: Industry Dynamics - The comments come amid ongoing discussions about the organization of Europe's defense industry, particularly the tensions between Airbus and Dassault regarding the Future Combat Air System (FCAS) fighter program [4][6]. - Even warns against industrial interests that may push for national programs, suggesting that such insular thinking could hinder broader European defense efforts [5].